News & Updates
Filter by Specialty:
ED-dispensed mifepristone plus misoprostol improves access to early pregnancy loss care
Administering mifepristone and misoprostol in the emergency departments (EDs) appears to be effective, increasing the availability of early pregnancy loss medical management services to women during the COVID-19 pandemic in the US, as shown in a study presented at the 2022 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting.
ED-dispensed mifepristone plus misoprostol improves access to early pregnancy loss care
16 May 2022
Beta-blockers reduce mortality risk in older patients with HFrEF
Use of beta-blockers results in a lower risk of all-cause mortality, but not of heart failure (HF) readmission, in older patients with HR with reduced ejection fraction (HFrEF), reports a recent study. Results are similar between patients admitted and not admitted from nursing homes.
Beta-blockers reduce mortality risk in older patients with HFrEF
16 May 2022
COVID-19 vaccine hesitancy persists in pregnant women despite recommendations
Acceptance rates of COVID-19 vaccines have remained unchanged among unvaccinated pregnant women following national recommendations, with nearly one-third of patients seeing the vaccine as something harmful to their pregnancy, according to a study.
COVID-19 vaccine hesitancy persists in pregnant women despite recommendations
16 May 2022
LDL-C test after ASCVD event improves statin adherence, intensification
Low-density lipoprotein cholesterol (LDL-C) testing appears to improve statin adherence and management in patients with a history of atherosclerotic cardiovascular disease (ASCVD), suggests a recent study.
LDL-C test after ASCVD event improves statin adherence, intensification
16 May 2022
Oral tebipenem pivoxil hydrobromide works against complicated UTI, acute pyelonephritis
Oral tebipenem pivoxil hydrobromide appears to be as good as intravenous ertapenem in the treatment of patients with complicated urinary tract infection (UTI) and acute pyelonephritis, with the two having a similar safety profile, according to data from a phase III study.
